<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04622631</url>
  </required_header>
  <id_info>
    <org_study_id>SHEBA-20- 6260-NK-CTIL</org_study_id>
    <nct_id>NCT04622631</nct_id>
  </id_info>
  <brief_title>Using 18F- FDG,18F-DOPA and 68Ga-DOTATATE PET/CT in Detection and Evaluation of Response in Patients With NET Undergoing PRRT</brief_title>
  <official_title>the Use of 18F-FDG, 18F-DOPA and 68Ga-DOTATATE PET/CT in Patients With NETs That Are Potential Candidates for PRRT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Nayruz Knaana</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      the investigators will follow up after patients with neuroendocrine tumors who undergo PRRT&#xD;
      treatment and evaluate the response for treatment using PET/CT with different tracers&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      patients with suspected or biopsy proven NET will undergo imaging using a Combination of 18F-&#xD;
      FDG , 18F-DOPA and 68Ga-DOTATATE PET/CT before the stat of PRRT . after two cycles of&#xD;
      treatment another two PET/CT are done using 18F- FDG and 18F-DOPA and about 6-8 weeks from&#xD;
      last treatment the patient will undergo PET/CT using 18F-DOPA .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 2020</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>Number of participants with good response to Peptide Receptor Radionuclide Therapy (PRRT)</measure>
    <time_frame>7 months</time_frame>
    <description>patients who have clinical and radiological improvement (using RECIST CRITERIA )</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with no response to Peptide Receptor Radionuclide Therapy (PRRT) treatment</measure>
    <time_frame>7 months</time_frame>
    <description>patients who have no clinical and radiological improvement or worsening in clinical condition or radiologic findings (RECIST )</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Neuroendocrine Tumors</condition>
  <arm_group>
    <arm_group_label>PRRT positive</arm_group_label>
    <description>patients who have good response to prrt treatment - the tumor and/or the metastatic disease show no uptake/activity on PET-CT scans</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PRRT negative</arm_group_label>
    <description>no response to PRRT treatment</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        patient with neuroendocrine tumor who were found to be eligible for Peptide Receptor&#xD;
        Radionuclide Therapy (PRRT)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patient with neuroendocrine tumor&#xD;
&#xD;
          -  eligible for PRRT&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  younger than 18 years old&#xD;
&#xD;
          -  pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>kanana yassin</last_name>
    <phone>0545680499</phone>
    <email>nayruz.knaana@sheba.health.gov.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>domachevsky</last_name>
    <email>Liran.Domachevsky@sheba.health.gov.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>kanana yassin</last_name>
      <phone>0545680499</phone>
      <email>nayruz.knaana@sheba.health.gov.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 30, 2020</study_first_submitted>
  <study_first_submitted_qc>November 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2020</study_first_posted>
  <last_update_submitted>November 9, 2020</last_update_submitted>
  <last_update_submitted_qc>November 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Sheba Medical Center</investigator_affiliation>
    <investigator_full_name>Dr. Nayruz Knaana</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>Peptide Receptor Radionuclide treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

